Myeloablative Cord Blood Transplantation for Adults With Hematological Malignancies Using Tacrolimus and Short-Term Methotrexate for Graft-Versus-Host Disease Prophylaxis: Single-Institution Analysis

摘要: Abstract We studied clinical outcomes of 25 adult patients with hematological malignancies who underwent cord blood transplantation (CBT) after a myeloablative conditioning regimen, including high-dose cytosine arabinoside (CA) (8 g/m 2 ), cyclophosphamide (CY) (120 mg/kg), and total-body irradiation (TBI) (12 Gy). For graft-versus-host disease (GVHD) prophylaxis, all received combination tacrolimus short-term methotrexate (sMTX). Neutrophil engraftment was achieved in 20 patients. Of the 22 evaluable patients, 7 had grades I II acute GVHD, respectively, only 1 developed grade III GVHD discontinuation due to encephalopathy. Chronic 13 19 4 extensive type. However, Karnofsky scores survivors at year CBT were 90% or 100%. Eight died nonrelapse causes (n = 4) relapse/progressive 4); 17 are currently alive 15 free present time (median follow-up, 24 months). The probability disease-free survival years among standard risk 89% that high-risk 30%. Transplantation-related mortality within 100 days 12%. These results suggested CA/CY/TBI is promising regimen for CBT. Furthermore, sMTX seemed have suppressed severe chronic which may also contribute favorable results.